Core Points - Novo Nordisk has completed the acquisition of Akero Therapeutics, announced on October 9, 2025, for $54 per share in cash, totaling an aggregated value of $4.7 billion, along with a Contingent Value Right (CVR) that could provide an additional $6 per share upon regulatory approval of Akero's lead candidate EFX [1][2]. Company Overview - Akero Therapeutics is a clinical-stage company focused on developing treatments for serious metabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, efruxifermin (EFX), is currently undergoing three Phase 3 clinical studies [5]. - Novo Nordisk is a global healthcare leader founded in 1923, with a mission to combat chronic diseases, particularly diabetes. The company operates in 80 countries and markets its products in around 170 countries [6].

Core Insights - Akari Therapeutics has announced promising preclinical data for its antibody-drug conjugate (ADC) AKTX-101, which targets Trop2 and shows potential in treating K-Ras G12V mutated pancreatic cancer, a highly lethal form of cancer with low survival rates [1][6] Industry Overview - Pancreatic cancer is one of the deadliest cancers, with approximately 60,000 new diagnoses and around 50,000 deaths annually in the U.S. The most common type, pancreatic ductal adenocarcinoma (PDAC), has limited treatment options, especially for K-Ras G12V mutation-driven tumors [2][3] Current Treatment Landscape - The standard treatments for K-Ras G12V-driven PDAC, such as FOLFIRINOX and gemcitabine plus nab-paclitaxel, yield poor outcomes with overall survival rates of 1.5 years and 1.3 years, respectively. There is a significant unmet need for targeted therapies in this area [3][4] AKTX-101 Mechanism and Efficacy - AKTX-101 is designed to deliver a novel RNA spliceosome modulating payload, PH1, to cancer cells expressing Trop2. This mechanism disrupts RNA splicing, which is crucial for cancer cell survival and proliferation. The ADC has shown significant cytotoxic potency in preclinical models, outperforming other investigational therapies [4][5] Future Development Plans - The company plans to present the preclinical data at a scientific conference and is advancing AKTX-101 towards a first-in-human trial expected to start in late 2026, with preliminary safety and efficacy data anticipated in 2027 [7]

Insilico Medicine aims to list in Hong Kong as soon as this month, sources say, rounding out a more than four-year effort to go public https://t.co/NJC3XkjMxq ...

Weinstein brings a global track record of transforming companies through value unlocking, and participation in over 20 M&A transactions and more than $5 billion in exits across healthcare, biotechnology, and nutrition.Weinstein’s ownership is expected to increase to approximately 30% on an issued and outstanding basis, reflecting his conviction in Pluri’s asset base, its valuation potential, and its long term strategy. HAIFA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri” or the “Company”) (N ...

Core Viewpoint - Eli Lilly and Company has successfully completed a tender offer to acquire Adverum Biotechnologies, with a cash payment of $3.56 per share and potential additional payments through contingent value rights [1][2][3] Group 1: Acquisition Details - The tender offer for Adverum's shares expired on December 8, 2025, with 16,493,335 shares tendered, representing approximately 64% of the outstanding shares [2] - The acquisition is expected to be finalized on December 9, 2025, in accordance with the Agreement and Plan of Merger dated October 24, 2025 [3] Group 2: Strategic Implications - The acquisition aims to enhance gene therapy capabilities, particularly for age-related conditions such as vision loss, as stated by Andrew Adams, Lilly's group vice president [4] - Adverum is focused on developing gene therapies for ocular diseases, with a proprietary platform designed to provide durable treatments through single-administration therapies [6]

Core Insights - FOXO Technologies Inc. announced that its behavioral health subsidiary, Myrtle Recovery Centers, was recognized by the Rural Health Association of Tennessee for its contributions to community health [1][2] - Myrtle Recovery Centers has been operational for two years, serving patients from 63 of Tennessee's 95 counties, highlighting the demand for accessible recovery-focused care [2] - The recognition emphasizes the importance of expanding treatment access in rural areas and reflects the effectiveness of Myrtle's treatment plans [3] Company Overview - FOXO operates four principal subsidiaries, including Myrtle Recovery Centers, which is a 30-bed behavioral health facility providing inpatient and outpatient services [5][4] - Myrtle Recovery Centers has been operating at capacity for most of 2025 and plans to expand its facilities to increase service capacity [3] - The CEO of FOXO expressed pride in Myrtle's impact on behavioral health needs in rural communities and supports the strategy of replicating Myrtle's care model across Tennessee [4]

Core Insights - 100% of patients in Cohorts 1-3 remain free of cytokine release syndrome, indicating a strong safety profile for the CD3 design used in the study [1] - The study evaluates mipletamig, a CD123 x CD3 bispecific molecule, in combination with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia patients unfit for intensive chemotherapy [1] - Preliminary results were presented at the American Society of Hematology Annual Meeting, highlighting the potential of the ADAPTIR™ and ADAPTIR-FLEX™ platform technologies developed by the company [1] Company Summary - Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics [1] - The company utilizes proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies in its research and development efforts [1] Industry Context - The ongoing Phase 1b/2 RAINIER study is significant for the treatment of acute myeloid leukemia, particularly for patients who cannot undergo intensive chemotherapy [1] - The combination of mipletamig with standard treatments like azacitidine and venetoclax represents a potential advancement in the therapeutic options available for AML [1]

Core Insights - Guardant Health, Inc. has successfully launched FPG 360, an in-house liquid biopsy testing service at Policlinico Gemelli in Rome, Italy [1] - This launch is part of a series of public-private partnerships that Guardant Health has established with leading European academic and research hospitals [1] Company Developments - The introduction of FPG 360 marks a significant advancement in precision oncology services offered by Guardant Health [1] - The partnership with Policlinico Gemelli highlights the company's commitment to integrating its innovative testing solutions within prominent healthcare institutions in Europe [1]

SENTI-202-101 Promising Results in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Ongoing Phase 1 Trial (SENTI-202-101) December 9, 2025 Conference Call and Webcast NASDAQ: SNTI | sentibio.com Forward Looking Statements This presentation contains forward-looking statements of Senti Biosciences, Inc. ("we," "us," "our") within the meaning of the Private Securities Litigation Reform Act of 1995. Statements we make in this presentation may include statements which are not historical f ...

5 of 8 patients (62.5%) achieved Undetectable MRD (uMRD) LEXINGTON, Mass., Dec. 9, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated clinical data from the ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104) in a poster presentation at the 67th ASH Annual Meeting (ASH). The AML triplet study is evaluating the addition of ...